$33.31
Value $2.2B
LKFT and LLY stock compared: price, dividend, valuation and results, from SEC filings.
$33.31
Value $2.2B
$1,347.11
Value $1.27T
Lakefront Biotherapeutics (LKFT) has a market value of $2.2B and Eli Lilly and Company (LLY) $1.27T. Over the last year, with dividends, LKFT moved +9.2% and LLY +29.1%. The P/E is 5.8 for LKFT and 46.1 for LLY. Dividend yield: LKFT none, LLY 0.47%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LKFT$2.2B
LLY$1.27T
LLY is 579 times LKFT
Revenue, 12 months
LKFT$1.3B
LLY$86.5B
LLY is 66 times LKFT
Net income, 12 months
LKFT$377M
LLY$27.6B
LLY is 73 times LKFT
Operating margin
LKFT26.5%
LLY–
ROIC
LKFT7.2%
LLY35.5%
28.3 points apart
P/E
LKFT5.8
LLY46.1
LLY is 7.9 times LKFT
Dividend yield
LKFT0.0%
LLY0.5%
0.5 points apart
5-year return
LKFT-35.3%
LLY+439.5%
474.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LKFT-35.3%
LLY+439.5%
| Period | LKFTWith dividends | LLYWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +9.2%Price +9.2% | +29.1%Price +28.3% |
| 3 years since November 20, 2023 | -10.9%-3.8% a yearPrice -10.9% | +130.0%+32.0% a yearPrice +125.4% |
| 5 years since November 19, 2021 | -35.3%-8.3% a yearPrice -35.3% | +439.5%+40.1% a yearPrice +416.7% |
| 10 years since November 22, 2016 | -42.5%-5.4% a yearPrice -42.5% | +1,962.1%+35.3% a yearPrice +1,672.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LKFTLakefront BiotherapeuticsLLYEli Lilly and Company
| Price | $33.31 | $1,347.11 |
|---|---|---|
| Market value | $2.2B | $1.27T |
| Enterprise value (EV) | $2.1B | $1.32T |
| P/E | 5.8 | 46.1 |
| P/E, 5-year median | 11.5 | 49.9 |
| P/B | 0.6 | 31.6 |
| EV/EBIT | 6.1 | 37.8 |
| Free cash flow yield | – | 1.6% |
| Revenue, 12 months | $1.3B | $86.5B |
|---|---|---|
| Net income, 12 months | $377M | $27.6B |
| Free cash flow, 12 months | -$318M | $19.7B |
| Earnings per share, 12 months | $5.72 | $30.81 |
| Revenue growth, year on year | 303.5% | 44.7% |
| Revenue growth a year, past | +18.4%over 5 years | +21.6%over 5 years |
| EPS growth a year, past | – | +27.6%over 5 years |
| Gross margin | 97.3% | 83.6% |
|---|---|---|
| Operating margin | 26.5% | – |
| Net margin | 28.8% | 31.9% |
| ROIC | 7.2% | 35.5% |
| ROE | 9.9% | 88.6% |
| Cash | $103M | $4.9B |
|---|---|---|
| Total debt | $8.1M | $49.5B |
| Net debt / EBITDA | – | 1.2 |
| Interest cover | – | 38.9× |
| Dividend yield | – | 0.5% |
|---|---|---|
| Dividend per share, 12 months | – | $6.34 |
| Dividend growth a year, past | – | +15.2%over 5 years |
| Buyback yield | – | 0.3% |
| Shareholder yield | – | 0.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.27T) is about 578.9 times Lakefront Biotherapeutics ($2.2B), at today's prices.
Since November 22, 2016, LKFT's price moved -42.5% and LLY's +1,672.7%. With dividends: LKFT -42.5% (-5.4% a year), LLY +1,962.1% (+35.3% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Lakefront Biotherapeutics and 0.47% for Eli Lilly and Company. Over the last twelve months they paid – and $6.34 per share.
At today's price, the P/E is 5.8 for LKFT and 46.1 for LLY. The median of the last five years was 11.5 and 49.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 28.8% for Lakefront Biotherapeutics and 31.9% for Eli Lilly and Company, and the operating margin 26.5% and –. Revenue was $1.3B and $86.5B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.